4-[(1R,2R)-2-[2-(3-bromophenyl)ethoxy]cyclohexyl]morpholine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(1R,2R)-2-[2-(3-bromophenyl)ethoxy]cyclohexyl]morpholine
• 化学式: C₁₈H₂₆BrNO₂
• 分子量: 368.3
• InChiKey: PJWYGBZUVBVWTP-QZTJIDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF
  申请人：Bain I. Allen

  公开号：US20050192208A2

  公开（公告）日：2005-09-01

  Abstract of the Disclosure Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

  本发明披露了调节离子通道的化合物。本发明的化合物可以被纳入组合物和试剂盒中。本发明还披露了化合物和组合物的多种体外和体内用途，包括治疗心律失常以及产生镇痛和局部麻醉。
• Aminocyclohexyl ether compounds and uses thereof
  申请人：Cardiome Pharma Corp.

  公开号：EP1422217A2

  公开（公告）日：2004-05-26

  Aminocyclohexyl ether compounds of formula (I), or a solvate or pharmaceutically acceptable salt thereof: are disclosed. In said formula, A, X and R, -R5 have the meanings given in the description. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

  公开了式 (I) 的氨基环己基醚化合物或其溶解物或药学上可接受的盐： 已公开。 在所述式中，A、X 和 R, -R5 具有描述中给出的含义。本发明的化合物可加入组合物和试剂盒中。本发明还公开了化合物和组合物的多种体外和体内用途，包括治疗心律失常、产生镇痛和局部麻醉。
• Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
  申请人：Cardiome Pharma Corp.

  公开号：EP2462933A1

  公开（公告）日：2012-06-13

  The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6.

  本发明提供了使用离子通道调节化合物（包括盐酸vernakalant）治疗和预防心律失常和其他疾病或紊乱的方法。本发明进一步提供了盐酸维纳卡兰的控释口服制剂和剂量，可有效预防心律失常。本发明的某些方法和制剂适用于治疗和预防因编码细胞色素 P450 2D6 基因的多态性而导致药物代谢改变的受试者的心律失常和其他疾病或紊乱。
• Uses of ion channel modulating compounds
  申请人：Beatch N. Gregory

  公开号：US20050026993A1

  公开（公告）日：2005-02-03

  Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.

  治疗或预防心律失常（包括治疗或预防心房颤动）的方法、制剂、给药方案和给药途径。在这些方法中，通过对受试者施用一种或多种离子通道调节化合物来治疗或预防疾病或病症，其中离子通道调节化合物可在受试者体内产生特定的血浆水平。离子通道调节化合物可以是环烷基胺醚化合物，特别是环己胺醚化合物。
• AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF
  申请人：Nortran Pharmaceuticals Inc.

  公开号：EP1087934B1

  公开（公告）日：2004-02-25